|
|
Article: Allergan Comments on the United States Department of Justice Subpoena for the Production of Documents Relating to Promotional Practices of BOTOX(R) for Therapeutic Uses.
- Article from:
- Business Wire
- Article date:
- March 4, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
IRVINE, Calif. -- Allergan, Inc. (NYSE: AGN) today announced that it received a subpoena from the United States Department of Justice, United States Attorney's Office for the Northern District of Georgia requesting the production of documents regarding promotional practices involving BOTOX([R]) (botulinum toxin type A) for therapeutic indications.
The subpoena broadly requests documents regarding promotional, educational and other activities relating to BOTOX([R]). Allergan's current understanding is that the inquiry involves questions regarding alleged off label promotion relating to the use of BOTOX([R]) for the treatment of headache. While Allergan is ...